Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:HGEN

Humanigen (HGEN) Stock Price, News & Analysis

Humanigen logo

About Humanigen Stock (NASDAQ:HGEN)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.06 million shs
Average Volume
3.26 million shs
Market Capitalization
$24,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Receive HGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter.

HGEN Stock News Headlines

Humanigen, Inc. (HGEN)
0KB1.SG,0P00011RKD,0 (0KB1.SG)
Shocking footage from Bill Gates’ $100,000,000,000 AI Bet
If you missed out on Nvidia, watch this video I just made.
Humanigen Inc (0KB2.BE)
Humanigen Inc HGENQ
Firm Retention Summary: Humanigen
See More Headlines

HGEN Stock Analysis - Frequently Asked Questions

Humanigen, Inc. (NASDAQ:HGEN) posted its earnings results on Friday, November, 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.14. The business had revenue of $1.04 million for the quarter, compared to analysts' expectations of $0.40 million.

Humanigen's stock reverse split on Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Humanigen investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Pfizer (PFE) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/12/2021
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:HGEN
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.70 million
Book Value
($0.45) per share

Miscellaneous

Free Float
93,240,000
Market Cap
$24,000.00
Optionable
No Data
Beta
-1.04
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:HGEN) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners